FDG-PET/CT for Simulation and Radiation Treatment Planning of Early Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01432002|
Recruitment Status : Active, not recruiting
First Posted : September 12, 2011
Last Update Posted : May 16, 2017
The purpose of the study is:
- to assess the potential benefits of 18F-[FDG] PET/CT and PET/MRI for operable breast cancer in order to define the size and location of the primary tumor, as well as axillary, supraclavicular and internal mammary lymph nodes.
- to apply the imaging results to the simulation and the radiation treatment planning and partial breast for 3-D radiation treatment and partial breast irradiation with intensity modulated radiation treatment (IMRT).
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||Application of 18F-[FDG] PET/CT to Simulation and Planning of Radiotherapy (RT) for Breast Cancer. Definition of Target Volume for 3-D RT and for Partial Breast Irradiation (PBI) by IMRT Technique|
|Study Start Date :||November 2007|
|Actual Primary Completion Date :||May 2013|
|Estimated Study Completion Date :||December 2017|
- Drawing of target volumes [ Time Frame: Up to 12 weeks after surgery ]Compare the drawing of target volumes using the PET/CT, PET/IRM information, or without these imaging informations.
- Correlate the FDG PET/CT PET/IRM with surgical pathology findings [ Time Frame: Up to 12 weeks after surgery ]Compare the pre-operative imaging information with histopathological description of the resected primary tumor, and with the extent of lymph node involvement.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01432002
|Radiation oncology, Geneva University Hospitals|
|Geneva, Switzerland, 1205|
|Principal Investigator:||Vincent Vinh-Hung, MD, PhD||Radiation Oncology, Geneva University Hospitals|